Samuels E R, Hou R H, Langley R W, Szabadi E, Bradshaw C M
Psychopharmacology Section, Division of Psychiatry, University of Nottingham Medical School (Room B109), Queen's Medical Centre, Nottingham, UK.
Psychopharmacology (Berl). 2006 Sep;187(4):498-510. doi: 10.1007/s00213-006-0443-y. Epub 2006 Jun 27.
In a previous study in healthy volunteers, the anti-Parkinsonian drug pramipexole caused sedation and pupil dilatation, consistent with the stimulation of inhibitory D(2)/D(3) autoreceptors on the ventral tegmental area dopaminergic neurones. The sedation may be related to the removal of the dopaminergic excitation of the locus coeruleus (via the meso-coerulear pathway), whereas the pupil dilatation may be due to the removal of the dopaminergic excitation of the Edinger-Westphal nucleus (via a putative meso-pupillomotor pathway).
We investigated the hypothesis that amisulpride, a D(2)/D(3) receptor antagonist, would have effects opposite to those of pramipexole on alertness, pupillary and endocrine functions.
Pramipexole (0.5 mg), amisulpride (50 mg), and their combination were administered to 16 healthy males in a balanced, cross-over, double-blind design. Tests included measures of alertness (Pupillographic Sleepiness Test, critical flicker fusion frequency, visual analogue scales), pupillary functions (resting pupil diameter, light and darkness reflex responses), non-pupillary autonomic functions (heart rate, blood pressure, salivation, core temperature), and endocrine functions [blood concentrations of prolactin, growth hormone (GH) and thyroid stimulating hormone (TSH)]. Data were analysed by ANOVA.
Pramipexole reduced alertness and pupillary light reflex response amplitude, tended to reduce core temperature, reduced prolactin levels and increased GH levels. Amisulpride reduced pupil diameter, increased the amplitude of the light reflex response and prolactin and TSH levels.
The opposite effects of pramipexole and amisulpride on alertness, pupillary function and pituitary hormone levels are consistent with their interactions with inhibitory D(2)/D(3) receptors on VTA neurones and in the tuberoinfundibular system.
在之前一项针对健康志愿者的研究中,抗帕金森病药物普拉克索会引起镇静和瞳孔扩张,这与腹侧被盖区多巴胺能神经元上抑制性D(2)/D(3)自身受体受到刺激一致。镇静作用可能与蓝斑去甲肾上腺素能神经元多巴胺能兴奋的消除有关(通过中脑-蓝斑通路),而瞳孔扩张可能是由于动眼神经副核多巴胺能兴奋的消除(通过一条假定的中脑-瞳孔运动通路)。
我们研究了如下假设,即D(2)/D(3)受体拮抗剂阿立哌唑对警觉性、瞳孔和内分泌功能的影响与普拉克索相反。
采用平衡、交叉、双盲设计,对16名健康男性给予普拉克索(0.5毫克)、阿立哌唑(50毫克)及其组合。测试包括警觉性测量(瞳孔描记嗜睡测试、临界闪烁融合频率、视觉模拟量表)、瞳孔功能(静息瞳孔直径、光反射和暗反射反应)、非瞳孔自主功能(心率、血压、唾液分泌、核心体温)以及内分泌功能[催乳素、生长激素(GH)和促甲状腺激素(TSH)的血药浓度]。数据采用方差分析。
普拉克索降低了警觉性和瞳孔光反射反应幅度,倾向于降低核心体温,降低催乳素水平并升高GH水平。阿立哌唑减小了瞳孔直径,增加了光反射反应幅度以及催乳素和TSH水平。
普拉克索和阿立哌唑在警觉性、瞳孔功能和垂体激素水平上的相反作用与其与腹侧被盖区神经元和结节漏斗系统中抑制性D(2)/D(3)受体的相互作用一致。